ProfileGDS5678 / 1433640_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 87% 87% 85% 83% 83% 86% 88% 84% 83% 84% 85% 85% 86% 85% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 16.5616387
GSM967853U87-EV human glioblastoma xenograft - Control 26.7109687
GSM967854U87-EV human glioblastoma xenograft - Control 36.4270785
GSM967855U87-EV human glioblastoma xenograft - Control 46.2675383
GSM967856U87-EV human glioblastoma xenograft - Control 56.1043283
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 16.3078286
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 26.6040288
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 36.1761984
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 46.0794883
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 16.3121284
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 26.3248985
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 36.4376385
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 46.5540386
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 56.3144285